Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).
Follow-Up Questions
Who is the CEO of Clinuvel Pharmaceuticals Ltd?
Dr. Philippe Wolgen is the Chief Executive Officer of Clinuvel Pharmaceuticals Ltd, joining the firm since 2005.
What is the price performance of CLVLY stock?
The current price of CLVLY is $7.8, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Clinuvel Pharmaceuticals Ltd?
Clinuvel Pharmaceuticals Ltd belongs to Biotechnology industry and the sector is Health Care
What is Clinuvel Pharmaceuticals Ltd market cap?
Clinuvel Pharmaceuticals Ltd's current market cap is $391.2M
Is Clinuvel Pharmaceuticals Ltd a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Clinuvel Pharmaceuticals Ltd, including 3 strong buy, 5 buy, 2 hold, 0 sell, and 3 strong sell
